Yes, good morning and a very warm welcome to this Scandion Oncology earnings call on our Q3 interim report for 2021. My name is Bo, and I'm the CEO of the company, and I'm here with the company's CFO, Johnny Stilou. It is a pleasure to present the results today from the third quarter. During the third quarter at Scandion Oncology, we have continued our transformation towards becoming the cancer drug resistance company. This is in accordance with our strategy. We are now to turn the page. Next page, please. First, a disclaimer because there might be forward-looking statements during this presentation. Next slide, please. We're on slide three. What we're gonna spend time on today is highlights from the Q3 and give you an overview on the clinical pipeline. Johnny will take over and give you the financial updates on the numbers for Q3. Finally, we will speak to an outlook for the coming period and also where you can meet the company. Now, next slide. Slide four. Let me remind you why I'm here, why we are here, and what it is that we get up to do every morning coming to work at Scandion Oncology. It is important to really visualize that close to 10 million lives are lost every year to cancer. This means that people are dying from cancer every day. 90% of cancer deaths are due to resistance in the tumors towards the existing cancer therapies. Now, there are new therapies coming. One of those areas is in immuno-oncology. It is estimated that even though immuno-oncology agents show potency and effect, it is for a limited number of people. In certain indications, only 13% of patients respond to immuno-oncology. Next slide, please. If we look at what we achieved in Q3, I'm proud to say that this has been another active quarter for Scandion Oncology. I mean, we've managed to achieve progress both in our intellectual property space. We have expanded our clinical trials to international trial sites, Germany. We have reported new data in the area of immuno-oncology from our collaboration with Alligator Bioscience and concluded that feasibility study. We have also strengthened and amended our clinical studies, and we have built on our people side. Our advisory board has brought, notably, people to the company that we can play ball with when we evolve and develop the strategies. Last but not least, we have conducted the company's first Capital Markets Day, where we were pleased to lay out the path for the company in the coming years. Now, since Q3 ended, we have also reported that we have adapted or adjusted our timelines in our PANTAX phase Ib trial, and I'll get back to that. Now, next slide. Slide six. As I said, one of the achievements here is that we have built in accordance with our strategy, our clinical advisory board. We started out with Richard Schilsky a while back, and then in this quarter, we announced that we managed to attract Dr. Josep Tabernero, Dr. Eric Van Cutsem, and Dr. Thomas Seufferlein to the clinical advisory board. These are really experienced, deeply experienced in the areas of oncology where we are developing and a group of people who have seen almost all trials in the area and that we can ask for advice and guidance in relation to how we develop the company. Next slide, please. On slide seven, Scandion Oncology, as I said, hosted its first Capital Markets Day, and it was a pleasure to be able to actually speak about what we have on the inside of the company, how we are thinking, and how we have focused our clinical strategies in order to have a clear path to market for SCO-101. This is one important achievement or milestone from that day. We also managed to lay forward how we see the market opportunities for SCO-101 and how we see several paths. We were particularly intrigued to actually speak to the unique mode of action that we have identified from our CORIST trial of SCO-101. In case you missed it, the recordings of the Capital Markets Day can be accessed from our company homepage. Next slide, please. On slide eight, we also recently announced that we have to adjust our timelines in our second clinical trial, PANTAX. This is a phase Ib study, and the readout is postponed. Let me say here up front that the trial is doing well. It's actually doing as well as we could have hoped for. Phase I trials have been particularly difficult to predict in terms of timelines in the years we've just been through. This is not only a fact for Scandion Oncology. It has been, for us, more challenging to recruit patients than we had anticipated. Our clinical sites opened slower than what we had planned for. As a result, we expanded the trial and it was a strategy for the company to internationalize the study. We opened in Germany, where the German competent authorities, in dialogue with us, required a staggered design, which is not unique for Scandion Oncology's trials but is something that the German authorities rely on. This is in a phase I trial where we're setting the dose and the safety, a very common phenomenon. The readout is postponed from the original plans and is now expected in Q2, Q3 of 2022. Let me say again, disregarding this delay, the study is really performing well and as well as we could have hoped for at this point in time. Next slide. Let me then bring the attention to our clinical pipeline. Just to reiterate, we have two ongoing clinical trials. For a company of Scandion Oncology's size, I'm proud to say that we are progressing in both trials, CORIST, where SCO-101 is being combined with FOLFIRI in metastatic colorectal cancer patients who have RAS wild-type tumors, and our PANTAX trial in metastatic or inoperable pancreatic cancer, where we combine SCO-101 with the standard of care. We are also developing our biomarker strategy in order to enable a precision medicine approach. Just to reiterate, our readouts, the next readouts from our clinical pipeline will be in CORIST in the range Q2-Q3 2022, and PANTAX in Q2-Q3 2022. With that, I will pass the baton to Johnny, who will take you through the numbers. Thank you very much. If we jump to slide 11, which is the financial overview slide. Here you have the overview of the result of the quarter and year to date. The net loss of the quarter, Q3 2021, shows a loss of DKK 15 million compared to the similar quarter last year, 2020, which was a loss of DKK 4 million. Year to date, for the first nine months, 2021 shows a net loss of DKK 36 million. This compares to DKK 11 million for the same quarter of last year. The numbers and the result is completely in line with our expectations. The result is driven by our operating cost. If we just take a look into those cost lines here, the staff cost and other expenses, I'll compare them to the previous quarter, Q2. Staff cost in Q3, which you can see is realized with DKK 7.1 million. That is an increase of DKK 1.7 million compared to Q2, which was realized with DKK 5.3 million. The increase is, as it says in the line above, due to the continued strengthening of the organization to execute on our clinical programs and to execute on our company strategy as presented. The other expense line is combined of two major cost areas. One is our clinical studies and the other is general and admin. The clinical study line shows a decrease in cost compared to the previous quarter. Overall, the cost is realized with DKK 8.3 million. Q2 was DKK 10.1 million. Driven by a timing of when costs are incurred in the clinical studies, which shows a decline as expected in Q3. We expect that according to plan, the clinical study cost will increase over the coming quarters. I'll get back to that shortly. General and admin, on the other hand, shows an increase quarter-over-quarter compared to Q2, and this is mainly driven by an increase we've seen in legal costs due to the increase in legal activities we have had over the past months. Go to the next slide 12. Cash position at end of September, we had a cash position of DKK 117 million. That reflects a cash spend in Q3 of DKK 14 million. As I said just before, we do expect to see increased costs over the coming quarters. As we progress through our two clinical studies, CORIST and PANTAX, that is according to our previous plans. We therefore also restate that current funding will still take us into 2023 as we have previously announced. With that, I'll give the word back to Bo to take us home. Yeah. Thank you, Johnny. Let me just conclude this presentation with expected significant events, which are on slide 13. These events do not include upcoming extraordinary general meetings, but more focused on our pipeline development. In Q2, Q3, our readout from CORIST will come next year. This is the second part of CORIST, so the proof of concept arm. Likewise, PANTAX will read out in the same range, Q2, Q3 of 2022, and we expect to set a dose for the combination of SCO-101 with nab-paclitaxel and gemcitabine. Our financing is secured until into 2023. Next slide, please. If you're keen to hear more about Scandion Oncology, there are a number of events coming up. Starting today, this afternoon, I'll be presenting at Dansk Aktionærforening, their Investor Week. November 24th, we will present the company at the Copenhagen School of Economics Investor Life Science Conference. January 12th, the company will be presenting at the Biotech Showcase at the JP Morgan Conference in San Francisco. January 20th, we'll be on Redeye's Fight Cancer event. January 25th, we will be presenting the company to stakeholders, investors, and potential business partners at the Swiss Nordic Bio. Next slide. The things that we will be presenting is obviously why we think that Scandion Oncology is such an interesting company to be part of and join. Let me just say briefly, we are first movers in cancer drug resistance. We are meeting a high medical need in a yet established market. We have de-risked our clinical assets and are continuing to de-risk them. We have a highly focused pipeline in cancer drug resistance, and we have focused our clinical development. The company is run and harbored by a seasoned leadership team and have advisors to complement that. We have multiple value inflection points coming up in the next period. With that said, I would like to thank you all for listening in today, and we'll be happy to entertain a dialogue through a Q&A. Over to the operator. Thank you ladies and gentlemen if you do wish to ask a question please press zero one on your telephone keypad now. If you wish to withdraw your question you may do so by pressing zero two to cancel. Once again if you have an audio question for speakers please press zero one on your telephone keypad now. Our first question comes from the line of Christian Binder from Redeye. Please go ahead. Your line is now open. Good morning, and thanks for taking my questions. Two quick ones. First, does the delay in PANTAX phase Ib top-line data change your business development strategy for SCO-101 in any way? For example, when you might consider entering any sort of partnership? Hello, Christian, and good morning, and thanks for the question. As to a change in our strategy for business development, this is a shift in a postponement of the readout. It's a short delay. As I said, we see good progress in the trial. This delay does not change or alter our business development strategies. Just to second that, as I've said previously, we see an area for potential partnering discussions in the area of pursuing SCO-101 with chemotherapy and immuno-oncology. This is still unchanged, completely unimpacted by PANTAX shift in readout. Got it. Second one, the delay in PANTAX data seems to be pretty minor, but still the share price reacted pretty negative on the announcement. Do you think there was kind of a misunderstanding, how much impact the news would have? Yes. Thanks for the question. I think that in terms of building value in the company, I'm focused very much on building the fundamental value, and I'm pleased to say that we have achieved a number of the things which were highlighted today. That said, I think that we can always discuss what is the right reaction to this. Let me just reiterate that we are focused on progressing the company. As I've said a couple of times today, the PANTAX shift in timelines is just due to some changes in the recruitment rates and building up sites, and we see this trial progressing well. All right. Got it. Thanks so much. That was all my questions. Have a good day. Thank you. Thank you. Once again, I remind you, if you do wish to ask an audio question, please press zero one on your telephone keypad now. There are currently no further audio questions. I will hand back to the speakers for any questions from the web platform. Thank you. Thank you. We have received a few questions. First question is, CORIST is now in proof of concept phase. Will you let the market know when, if POC is reached according to Simon's two-stage design? We will, of course, inform the market as soon as we have results from the CORIST trial, conclusive results, and at that time point, we will let the market know what the state of that results are. Thank you. Another question is, when will we know more regarding data from immuno-oncology, and is there a possibility for a future combination study with SCO-101 chemo and immuno-oncology? I think in general, as we've said, we see an opportunity in exploring further, the potential of combining SCO-101 with different modalities for different modulators of immuno-oncology. I think that at this point in time, it's too early to say when we will know more. We'll let the market know as soon as we have matured our thinking and have results to go with it. We do see a potential for exploring this further. Thank you. Another question in relation to the PANTAX study. Is there still 12-18 patients to be included in PANTAX part one, and will you make some kind of interim press release during the study? In terms of our readout in general, we like to report the market with clear information. I understand the eagerness to understand what is going on, but we want to report conclusive data. When it comes to a phase I trial, it's a dose escalation trial. It's, at this point in time, as we haven't concluded the trial, impossible to say how many patients will end up being included because that depends on how far up in dose we can get in the given combination that we are testing. Let me just elaborate with one sentence on that. I think that this means that the higher we can go, the more patients we need to include. In that regard, it can take longer, but it also means that the safety margin gets higher or larger. This is the way that you should see this. We will inform the market again as soon as we have conclusive results. Thank you. Another question in relation to the PANTAX study. It is, what do you mean with the study is performing as well as we could have hoped for? Can you see effect in the dosed patients? As I've just said it to the previous question or the previous asker, we will report from the trial when we have concluded it. Prior to that, it's too preliminary or too early to say anything from the trial, and I think that that's in respect for the market and our shareholders. Thank you. We have a question for CORIST. What is the status for CORIST part three? When will you start this part, and when is it expected to read out? When it comes to the development plans for CORIST further, you know, I guide you to the information that we have released so far, and we will inform the market on the detailed plans as to when you can expect CORIST 3 to commence. Thank you. We have another question. Will the company attend the Biotech Showcase in January in person or virtual? That's a good question. Right now, travel restrictions, as we are based in Scandinavia, and the Biotech Showcase is a physical event taking place in the U.S., this depends on unchanged situation in the travel restrictions. There might be a certain likelihood that we will attend in person. Thank you. We have one question here. What happened to the antibiotic SOM-001? The question is on the project known as SOM-001. I think this was addressed also at our Capital Markets Day, so I'm happy to bring it up again. First of all, we are focusing on overcoming chemotherapy resistance and cancer drug resistance. The antibiotic program was a very early exploratory study, which we tested with certain third parties as to the interest in the value of that and realized and decided that this was not on strategy and was not mature for monetizing. The program was parked. Thank you. We have another question. You announced on the Capital Markets Day that you want to enter the immuno-oncology space with SCO-101. Would you need a big partner to make a move into immuno-oncology? And when would you think that a partnership would make sense for Scandion? What I said is that we will explore and exploit what we have seen. That means that we will build on what we have seen in our preclinical studies in the area of immuno-oncology or the combination of SCO-101 with cytostatics or chemotherapy and immunotherapy. This is a plan that we are true to, and we are looking into the possibilities and what would be the right way to actually exploit that in the best fashion. Thank you. We have no further questions. Okay. With that, I would like to thank you for listening in, and happy to hear and see you again at the upcoming events or the next quarterly hearings. Back to the operator.